We found that BTKi treatment led to a reduction of NFATc1 mRNA levels (Supplementary Fig. 8C) and protein levels in some of the CLL samples (Fig. 4B and Supplementary 8A). Here, NFATC1 is linked to B-cell chronic lymphocytic leukemia.